Vaccine approaches conferring cross-protection against influenza viruses

Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model

(2017) Megan E. Ermler et al.   JOURNAL OF VIROLOGY

Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses

(2016) M. Gordon Joyce et al.   CELL

Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses

(2016) Attapon Kamlangdee et al.   JOURNAL OF VIROLOGY

An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice

(2016) Weiping Cao et al.   Nanomedicine-Nanotechnology Biology and Medicine

Supplementation of H1N1pdm09 split vaccine with heterologous tandem repeat M2e5x virus-like particles confers improved cross-protection in ferrets

(2016) Nedzad Music et al.   VACCINE

Supplemented vaccination with tandem repeat M2e virus-like particles enhances protection against homologous and heterologous HPAI H5 viruses in chickens

(2016) Byung-Min Song et al.   VACCINE

Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B

(2016) Xin Gong et al.   Emerging Microbes & Infections

Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine

(2016) Nuriban Valero-Pacheco et al.   PLoS One

Stalking influenza by vaccination with pre-fusion headless HA mini-stem

(2016) Sophie A. Valkenburg et al.   Scientific Reports

Flucelvax (Optaflu) for seasonal influenza

(2015) Ilaria Manini et al.   Expert Review of Vaccines

Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection

(2015) Hadi M Yassine et al.   NATURE MEDICINE

A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen

(2015) A. Impagliazzo et al.   SCIENCE

Immune history profoundly affects broadly protective B cell responses to influenza

(2015) Sarah F. Andrews et al.   Science Translational Medicine

Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age

(2015) Ruvim Izikson et al.   VACCINE

Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: Randomised, controlled trials

(2015) Isabel Leroux-Roels et al.   VACCINE

Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses

(2015) Teddy John Wohlbold et al.   VACCINE

Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies

(2015) José Garcia-Sicilia et al.   Human Vaccines & Immunotherapeutics

Protection against Influenza A Virus Challenge with M2e-Displaying Filamentous Escherichia coli Phages

(2015) Lei Deng et al.   PLoS One

Mucosal Immunization with a Candidate Universal Influenza Vaccine Reduces Virus Transmission in a Mouse Model

(2014) G. E. Price et al.   JOURNAL OF VIROLOGY

Broad Protection against Avian Influenza Virus by Using a Modified Vaccinia Ankara Virus Expressing a Mosaic Hemagglutinin Gene

(2014) A. Kamlangdee et al.   JOURNAL OF VIROLOGY

Modified Vaccinia Virus Ankara Encoding Influenza Virus Hemagglutinin Induces Heterosubtypic Immunity in Macaques

(2014) N. W. Florek et al.   JOURNAL OF VIROLOGY

Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection

(2014) V. V. A. Mallajosyula et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: Results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers

(2014) Jenny G.H. Low et al.   VACCINE

Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge

(2013) Xiao Gao et al.   ANTIVIRAL RESEARCH

Effectiveness of Seasonal Trivalent Influenza Vaccine for Preventing Influenza Virus Illness Among Pregnant Women: A Population-Based Case-Control Study During the 2010–2011 and 2011–2012 Influenza Seasons

(2013) Mark G. Thompson et al.   CLINICAL INFECTIOUS DISEASES

Single-Dose Vaccination of a Recombinant Parainfluenza Virus 5 Expressing NP from H5N1 Virus Provides Broad Immunity against Influenza A Viruses

(2013) Z. Li et al.   JOURNAL OF VIROLOGY

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

(2013) Janet E McElhaney et al.   LANCET INFECTIOUS DISEASES

Coadministration of Seasonal Influenza Vaccine and MVA-NP+M1 Simultaneously Achieves Potent Humoral and Cell-Mediated Responses

(2013) Richard D Antrobus et al.   MOLECULAR THERAPY

A Recombinant Viruslike Particle Influenza A (H7N9) Vaccine

(2013) Louis F. Fries et al.   NEW ENGLAND JOURNAL OF MEDICINE

Isolation of a High Affinity Neutralizing Monoclonal Antibody against 2009 Pandemic H1N1 Virus That Binds at the ‘Sa’ Antigenic Site

(2013) Nachiket Shembekar et al.   PLoS One

Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus

(2013) Alessandra Vitelli et al.   PLoS One

Examination of Influenza Specific T Cell Responses after Influenza Virus Challenge in Individuals Vaccinated with MVA-NP+M1 Vaccine

(2013) Timothy J. Powell et al.   PLoS One

Broadly Protective Adenovirus-Based Multivalent Vaccines against Highly Pathogenic Avian Influenza Viruses for Pandemic Preparedness

(2013) Sai V. Vemula et al.   PLoS One

Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection

(2013) So-Hee Kim et al.   PLoS One

Effectiveness of Inactivated Influenza Vaccines in Preventing Influenza-Associated Deaths and Hospitalizations among Ontario Residents Aged ≥65 Years: Estimates with Generalized Linear Models Accounting for Healthy Vaccinee Effects

(2013) Benjamin J. Ridenhour et al.   PLoS One

In vitroandin vivocharacterization of designed immunogens derived from the CD-helix of the stem of influenza hemagglutinin

(2013) V. Vamsee Aditya Mallajosyula et al.   PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice

(2013) Joseph N. Brewoo et al.   VACCINE

Assessment of Antigen-Specific and Cross-Reactive Antibody Responses to an MF59-Adjuvanted A/H5N1 Prepandemic Influenza Vaccine in Adult and Elderly Subjects

(2012) Iván Bihari et al.   Clinical and Vaccine Immunology

Preliminary Assessment of the Efficacy of a T-Cell–Based Influenza Vaccine, MVA-NP+M1, in Humans

(2012) Patrick J. Lillie et al.   CLINICAL INFECTIOUS DISEASES

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production

(2012) Emanuele Montomoli et al.   Expert Review of Vaccines

A Computationally Optimized Hemagglutinin Virus-Like Particle Vaccine Elicits Broadly Reactive Antibodies that Protect Nonhuman Primates from H5N1 Infection

(2012) Brendan M. Giles et al.   JOURNAL OF INFECTIOUS DISEASES

Recombinant Parainfluenza Virus 5 Expressing Hemagglutinin of Influenza A Virus H5N1 Protected Mice against Lethal Highly Pathogenic Avian Influenza Virus H5N1 Challenge

(2012) Z. Li et al.   JOURNAL OF VIROLOGY

A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo

(2012) G. S. Tan et al.   JOURNAL OF VIROLOGY

Cross-neutralization of influenza A viruses mediated by a single antibody loop

(2012) Damian C. Ekiert et al.   NATURE

A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years

(2012) Richard D. Antrobus et al.   PLoS One

Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses

(2012) N. Pica et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials

(2012) Carlos A. DiazGranados et al.   VACCINE

Corrigendum to “Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months” [Vaccine 29 (2011) 6408–6418]

(2012) George Risi et al.   VACCINE

Broadly neutralizing antibodies against influenza virus and prospects for universal therapies

(2012) Damian C Ekiert et al.   Current Opinion in Virology

New technologies for influenza vaccines

(2012) Philip Dormitzer et al.   Human Vaccines & Immunotherapeutics

Effectiveness of influenza vaccine in aging and older adults: comprehensive analysis of the evidence

(2012) Pierre-Olivier Lang et al.   Clinical Interventions in Aging

Immunogenicity and Safety of 2 Dose Levels of a Thimerosal-Free Trivalent Seasonal Influenza Vaccine in Children Aged 6–35 Months: A Randomized, Controlled Trial

(2012) Joanne M. Langley et al.   Journal of the Pediatric Infectious Diseases Society

Breaking B and T cell tolerance using cationic lipid–DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV

(2011) John D. Morrey et al.   ANTIVIRAL RESEARCH

Antibody Breadth and Protective Efficacy Are Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle Vaccines

(2011) Brendan M. Giles et al.   Clinical and Vaccine Immunology

Wide Prevalence of Heterosubtypic Broadly Neutralizing Human Anti-Influenza A Antibodies

(2011) J. Sui et al.   CLINICAL INFECTIOUS DISEASES

Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus

(2011) Mark W. LaMere et al.   JOURNAL OF IMMUNOLOGY

Safety and Immunogenicity of a Monovalent 2009 Influenza A/H1N1v Vaccine Adjuvanted With AS03A or Unadjuvanted in HIV-Infected Adults: A Randomized, Controlled Trial

(2011) Odile Launay et al.   JOURNAL OF INFECTIOUS DISEASES

Dose-Sparing H5N1 A/Indonesia/05/2005 Pre-pandemic Influenza Vaccine in Adults and Elderly Adults: A Phase III, Placebo-Controlled, Randomized Study

(2011) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

Regulation of Antinucleoprotein IgG by Systemic Vaccination and Its Effect on Influenza Virus Clearance

(2011) M. W. LaMere et al.   JOURNAL OF VIROLOGY

Protection against Divergent Influenza H1N1 Virus by a Centralized Influenza Hemagglutinin

(2011) Eric A. Weaver et al.   PLoS One

A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins

(2011) D. Corti et al.   SCIENCE

A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses

(2011) D. C. Ekiert et al.   SCIENCE

Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e

(2011) Ki Seok Park et al.   VACCINE

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months

(2011) George Risi et al.   VACCINE

Influenza virus-like particle can accommodate multiple subtypes of hemagglutinin and protect from multiple influenza types and subtypes

(2011) Peter Pushko et al.   VACCINE

Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice

(2011) Libo Dong et al.   VACCINE

Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1

(2010) T. K. Berthoud et al.   CLINICAL INFECTIOUS DISEASES

Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection

(2010) K. El Bakkouri et al.   JOURNAL OF IMMUNOLOGY

Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults

(2010) Joanne M. Langley et al.   JOURNAL OF INFECTIOUS DISEASES

A Universal Influenza A Vaccine Based on Adenovirus Expressing Matrix-2 Ectodomain and Nucleoprotein Protects Mice From Lethal Challenge

(2010) Dongming Zhou et al.   MOLECULAR THERAPY

Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine

(2010) Gary J Nabel et al.   NATURE MEDICINE

Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes

(2010) T. T. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

(2010) J.-M. Song et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months

(2010) Alfonso Carmona et al.   VACCINE

Broadly Protective Monoclonal Antibodies against H3 Influenza Viruses following Sequential Immunization with Different Hemagglutinins

(2010) Taia T. Wang et al.   PLoS Pathogens

Estimating Influenza-Associated Deaths in the United States

(2009) William W. Thompson et al.   AMERICAN JOURNAL OF PUBLIC HEALTH

Unraveling the Mystery of Swine Influenza Virus

(2009) Taia T. Wang et al.   CELL

Estimates of US influenza-associated deaths made using four different methods

(2009) William W. Thompson et al.   Influenza and Other Respiratory Viruses

A Trivalent Virus-Like Particle Vaccine Elicits Protective Immune Responses against Seasonal Influenza Strains in Mice and Ferrets

(2009) Ted M. Ross et al.   PLoS One

Antibody Recognition of a Highly Conserved Influenza Virus Epitope

(2009) D. C. Ekiert et al.   SCIENCE

Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone®) increases antibody response, cellular immunity, and antigenically drifted protection

(2009) Marla Lay et al.   VACCINE

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial

(2009) François Roman et al.   VACCINE

Efficacy of cationic lipid–DNA complexes (CLDC) on hepatitis B virus in transgenic mice

(2008) John D. Morrey et al.   ANTIVIRAL RESEARCH

A Broadly Protective Vaccine against Globally Dispersed Clade 1 and Clade 2 H5N1 Influenza Viruses

(2008) Mary A. Hoelscher et al.   JOURNAL OF INFECTIOUS DISEASES

Broad Cross-Protection against H5N1 Avian Influenza Virus Infection by Means of Monoclonal Antibodies that Map to Conserved Viral Epitopes

(2008) Yixin Chen et al.   JOURNAL OF INFECTIOUS DISEASES

Heterosubtypic Protection against Pathogenic Human and Avian Influenza Viruses via In Vivo Electroporation of Synthetic Consensus DNA Antigens

(2008) Dominick J. Laddy et al.   PLoS One

A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses

(2008) M.-W. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses

(2008) David H. Holman et al.   VACCINE